Receptor Mediated Transcytosis (Rmt) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
Receptor Mediated Transcytosis (Rmt) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Receptor-mediated transcytosis (RMT) is the primary strategy for delivering large biologic therapeutics across the blood-brain barrier (BBB). This transport mechanism exploits endogenous receptor systems that normally mediate uptake of essential nutrients and proteins into the brain.
RMT involves a multi-step process where a therapeutic molecule binds to a specific receptor on the brain endothelial cell surface, triggers internalization into clathrin-coated pits, and is then transported across the endothelial cell either to the brain parenchyma or back to the blood compartment.
A key insight in RMT design is the "affinity paradox" - lower receptor affinity often yields better brain delivery. High-affinity antibodies become trapped in endothelial cells and undergo lysosomal degradation, while lower-affinity antibodies more readily undergo productive transcytosis [1].
TfR1 is the most extensively studied target for RMT. It mediates iron uptake into the brain through transferrin binding.
Roche developed a bispecific antibody platform where one arm binds TfR1 and the other arm binds the therapeutic target [2].
Key features:
Denali Therapeutics developed a proprietary RMT platform using engineered Fc domains with enhanced TfR binding [3].
TV-platform antibodies:
| Drug | Company | Target | Indication | Status |
|---|---|---|---|---|
| Trontinemab | Roche | Aβ | Alzheimer's | Phase 2 |
| ABBV-951 | AbbVie | - | Parkinson's | Approved |
LRP1 is a large multi-ligand receptor that mediates uptake of various proteins and peptides across the BBB.
Angiopep-2 is a peptide derived from the Kunitz domain of aprotinin that binds LRP1 with high affinity [4].
The insulin receptor mediates insulin transport across the BBB, though its role in RMT is more limited than TfR1.
Human insulin receptor monoclonal antibody (HIRMAb) has been engineered as a brain delivery shuttle [5].
Features:
Clinical applications:
The LDL receptor family includes multiple members relevant to BBB transport:
| Receptor | Endogenous Ligand | Therapeutic Relevance |
|---|---|---|
| LDLR | LDL, VLDL | Limited |
| LDLRAP1 | ApoE | Gene therapy target |
| LRP2 (Megalin) | Various proteins | Kidney, not brain |
| LRP8 (ApoER2) | ApoE | Neuronal expression |
CD98hc (also known as 4F2hc or SLC3A2) is a newer target for RMT [6].
| Trial ID | Drug | Mechanism | Indication | Phase | Year |
|---|---|---|---|---|---|
| NCT05468879 | Trontinemab | Anti-TfR1 × Anti-Aβ | Alzheimer's | Phase 2 | 2022 |
| NCT04631458 | ABBV-951 | Prodrug + RMT | Parkinson's | Phase 3 | 2020 |
| NCT03634030 | ANG1005 | Angiopep-2-paclitaxel | Breast cancer brain mets | Phase 2 | 2018 |
| NCT01480548 | HIRMAb-Aβ | HIRMAb-anti-Aβ | Alzheimer's | Phase 1 | 2011 |
| Target | Advantages | Limitations | Clinical Progress |
|---|---|---|---|
| TfR1 | Well-validated, high expression | Affinity paradox, immune response risk | Advanced |
| LRP1 | Multi-ligand, well-characterized | Off-target effects | Phase 2 |
| Insulin Receptor | Endogenous transport | Limited capacity, metabolic effects | Phase 1 |
| CD98hc | Restricted expression | Early stage | Preclinical |
Receptor Mediated Transcytosis (Rmt) plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Receptor Mediated Transcytosis (Rmt) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
🔴 Low Confidence
| Dimension | Score |
|---|---|
| Supporting Studies | 6 references |
| Replication | 33% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 75% |
Overall Confidence: 39%